Biologic therapy of chronic myelogenous leukemia.
In a study using human IFN-alpha, 36 of 51 patients with chronic phase CML achieved a complete hematologic remission. More significantly, 20 patients showed suppression of Ph-positive metaphases with reappearance of cells with normal karyotype. To date, the authors have treated 44 chronic phase CML patients with recombinant IFN-alpha as their frontline biologic therapy with similar hematologic and cytogenetic responses. Gamma interferon is active against CML but less so than IFN-alpha. Chemotherapy followed by IFN-alpha also shows promise. Interferons have produced only limited responses in terminal phase CML patients.
Kantarjian
H M
HM
Department of Hematology, University of Texas, MD Anderson Hospital, Houston 77030.
Talpaz
M
M
Gutterman
J
J
D001752:Blast Crisis / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma